Sonnet BioTherapeutics Holdings Balance Sheet Health
Financial Health criteria checks 4/6
Sonnet BioTherapeutics Holdings has a total shareholder equity of $4.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $7.2M and $3.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.86m |
| Equity | US$4.04m |
| Total liabilities | US$3.15m |
| Total assets | US$7.18m |
Recent financial health updates
Recent updates
Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement
Oct 04Sonnet BioTherapeutics announces 1-for-14 reverse stock split
Sep 16Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia
Jul 22We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate
Dec 19
Sonnet Bio issued U.S. patent for its albumin binding technology
Jun 08Sonnet shares rise after completing licensing agreement with New Life Therapeutics
May 03Sonnet BioTherapeutics reports FY results
Dec 17Financial Position Analysis
Short Term Liabilities: SONN's short term assets ($6.7M) exceed its short term liabilities ($3.1M).
Long Term Liabilities: SONN's short term assets ($6.7M) exceed its long term liabilities ($23.6K).
Debt to Equity History and Analysis
Debt Level: SONN is debt free.
Reducing Debt: SONN currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SONN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SONN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 6% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/17 08:58 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sonnet BioTherapeutics Holdings, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |